A study from the University of Cambridge reveals that one year after stopping weight loss medications like Ozempic, individuals tend to regain about 60% of their lost weight, with a stabilization of rebound effects thereafter.
A recent study from the University of Cambridge highlights that after discontinuing weight-loss medications such as Ozempic and Wegovy, individuals on average regain approximately 60% of the weight they had lost within a year. Following this period, the rebound effect stabilizes, allowing patients to retain a 25% reduction in weight compared to their baseline before treatment. This suggests that while these medications can be effective for weight loss, the long-term sustainability of that weight loss remains a challenge for many users.
The research sheds light on the wider obesity epidemic affecting millions globally, which increases the risks of conditions like type 2 diabetes, cardiovascular diseases, and cancer. While losing weight can mitigate these health risks, the study underscores that relying solely on medication may not yield lasting results for all patients. The medications are designed to assist with blood sugar control and appetite reduction, and clinical trials indicate they can lead to significant weight loss ranging from 15% to 20%. However, the durability of these results is under scrutiny, as only about half of the patients who begin treatment stay on them for over a year.
This analysis raises critical considerations for both medical practitioners and patients regarding the use of newer generation weight-loss medications. It emphasizes the importance of combining pharmaceutical interventions with lifestyle changes such as diet and exercise for effective long-term weight management, addressing a significant public health concern that continues to impact diverse populations worldwide.
